Created on Tuesday, 05 Nov 2019. Posted in Costing
From April 2020, the NIHR’s online interactive Costing Tool (iCT) will be the only system available for industry costing submissions for new studies. There will be no further Excel templates produced after this time. Make sure you're ready for the big switchover and find out more about the iCT and how to get started here.
All NHS R&D Departments are encouraged to pro-actively work ahead of this deadline and register themselves with group CPMS accounts so that are able to receive new iCT requests from our commercial partners, meaning that negotiation timelines and setup are reduced to a minimum.
The NIHR has launched a new web-based costing tool for industry - which will enable faster and more efficient costing and contracting between the life sciences sector and the NHS during the study set-up phase. The online iCT will complement the existing Excel-based Industry Costing Template and both will continue to be available through the NIHR CRN Study Support Service Early Contact and Engagement service.
There has been a question about the amount by which applications may vary in cost between Stage 1 and Stage 2 and a perception that costs should not vary by more than 10%. The official position is now that “It is accepted that a variance in costs is likely to occur between Stage 1 and Stage 2, but costs at each stage should represent value for money. Advisory committees may provide project specific costing guidance/feedback following stage 1.”
Created on Friday, 05 Apr 2019. Posted in Costing
NHS England, the HRA and the NIHR have jointly developed a National Directive on Commercial Contract Research, which will enable a study-based approach across England to the costing and contracting elements of commercial contract research. Guidance has been published on the NIHR website, outlining what the new requirements for NHS providers in England will mean for the life sciences sector.
Created on Tuesday, 02 Oct 2018. Posted in Costing
There has been continued frustration about the complexity and variation in processes for commissioners and providers agreeing excess treatment costs (ETCs).To address the issues identified, the way in which excess treatment costs are met is changing and a trial period for the new arrangements will roll out from 1 October 2018, through to full implementation in April 2019.
To underpin the new arrangements, a cost attribution tool has been created in partnership with charity funders and research sponsors. This tool provides a standardised approach for attributing the costs of health and social care research and development (AcoRD) across England. As part of their funding applications, researchers will be required to complete this new tool, known as a Schedule of Events Cost Attribution Tool (SoECAT) for clinical research, which has been developed from the current HRA Schedule of Events. This tool is designed to capture the different costs associated with clinical research and attribute them accordingly.
The emphasis is on simplifying and improving research arrangements is ultimately intended to improve future health and care for patients. For more information and latest updates visit the NIHR website
Created on Monday, 09 Apr 2018. Posted in Costing
Working out the costings for an NIHR grant should be done with experts in the leading institution where the money will be held, but if you want an overview of what kinds of things can be costed into a bid and how accurate your costings are expected to be then take a look at the NIHR's finance document.
You need to be thinking about costing from the earliest stages of your project design. You should aim to contact the relevant Research Support Office(s), and Trust R&D offices, several weeks before the deadline and to have familiarised yourself with the current research costing guidance.
Consider the questions:
Attributing the costs of health and social care Research and Development (AcoRD)
The AcoRD guidance categorises the costs associated with research based on the nature of the activity and whether activities contribute to NHS patient care. Activities are divided into three categories, to which all research and development activities can be attributed:
A list of common research activities attributed using AcoRD are found in Annex A https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351185/AcoRD_Annex_A_-__List_of_Common_research_Activities_March_2013_for_publication.pdf
An very good introduction to cost-utility analysis for those wanting to gain a better understanding of one of the most widely-used form of economic evaluation in healthcare. Full article
There are a number of ways to recognise the contributions of members of the public who are actively involved in research. This INVOLVE resource links to guides and practical advice on payment and non-monetary methods for recognising the time, skills and expertise provided by members of the public.
The value of Excess Treatment Costs is not a large sum in the context of overall NHS funding but anecdotal evidence suggests that the (non) payment of Excess Treatment Costs has become a point of friction between providers and commissioners.
Excess Treatment Costs are the difference between the total treatment costs and the cost of standard treatment.
Excess Treatment Costs are part of treatment costs and therefore normal commissioning arrangements apply.
This new guidance on meeting Excess Treatment Costs relates specifically to non-commercial research (i.e. research funded by the NIHR, other areas of central Government including Research Councils, NIHR noncommercial Partners and also Investigator-initiated, commercial-collaborative studies (Industry-funded, non-industry sponsored studies).
It covers the following topics: